Lok Yun Louise Sin
Nurse Practitioner · Renton, WANPI 1083209514
Payments from drug & device makers
Across 691 payments — averaging $33.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Johnson & Johnson$2K
- AbbVie$1K
- Pfizer$1K
- Incyte Corporation$1K
- GSK$900
- plus $13K from 54 others
What the payments were for
- Food & beverage$21,45393%
- Education$1,5137%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,965 in reported general payments places this provider in the 95th percentile of 2,466 nurse practitioner providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 37 | $532,559 |
| CalquenceAcalabrutinib Maleate | 23 | $313,722 |
| RevlimidLenalidomide | 17 | $306,264 |
| XtandiEnzalutamide | 22 | $288,753 |
| ErleadaApalutamide | 19 | $280,580 |
| KeytrudaPembrolizumab | 17 | $173,901 |
| TagrissoOsimertinib Mesylate | 11 | $171,553 |
| Lenalidomide | 13 | $154,399 |
| OrgovyxRelugolix | 22 | $56,841 |
| XgevaDenosumab | 12 | $35,135 |
| EliquisApixaban | 11 | $7,498 |
| Imatinib Mesylate | 24 | $2,652 |
| Anagrelide Hcl | 22 | $2,456 |
| Letrozole | 103 | $2,105 |
| Anastrozole | 108 | $1,983 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCVerzenio | $546 | $532,55937 claims |
| AstraZenecaCalquence, Tagrisso | $2,919 | $485,27534 claims |
| Bristol Myers SquibbRevlimid | $500 | $306,26417 claims |
| Astellas Pharma US IncXtandi | $886 | $288,75322 claims |
| Johnson & JohnsonErleada | $2,498 | $280,58019 claims |
| MerckKeytruda | $631 | $173,90117 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $240 | $56,84122 claims |
| AmgenXgeva | $62 | $35,13512 claims |
| PfizerEliquis | $1,081 | $7,49811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,466 nurse practitioner providers in Washington.
Other nurse practitioner in Renton
- Darla ChapmanSeattle$541K
- Olga VoloshinaSeattle$279K
- Sandra ChristensenSeattle$244K
- Wayne ClarkYakima$232K
- Felicia ForrestLynnwood$206K
- Amaris MurphyBellevue$146K
- Sonia GlennieSeattle$78K
- Megan WildesTacoma$72K
- Kate KennedyBellevue$63K
- Vicki HainesPasco$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.